Cutler Group LP Cel Sci Corp Transaction History

Cutler Group LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 25, 2022	SELL	$3.09 - $5.23 $927 - $1,569	-300 Reduced 27.27%	800 $2,000
Q2 2022 Aug 04, 2022	BUY	$2.58 - $4.99 $774 - $1,497	300 Added 37.5%	1,100 $4,000
Q3 2021 Oct 26, 2021	SELL	$7.64 - $12.49 $272,984 - $446,280	-35,731 Reduced 97.81%	800 $8,000
Q2 2021 Jul 19, 2021	BUY	$8.68 - $27.49 $311,881 - $987,743	35,931 Added 5988.5%	36,531 $317,000
Q1 2021 Apr 26, 2021	SELL	$12.0 - $27.64 $33,708 - $77,640	-2,809 Reduced 82.4%	600 $9,000
Q4 2020 Jan 21, 2021	BUY	$11.05 - $16.62 $16,674 - $25,079	1,509 Added 79.42%	3,409 $39,000
Q3 2020 Oct 27, 2020	SELL	$11.69 - $14.54 $18,704 - $23,264	-1,600 Reduced 45.71%	1,900 $24,000
Q2 2020 Jul 22, 2020	SELL	$9.75 - $17.6 $2,925 - $5,280	-300 Reduced 7.89%	3,500 $52,000
Q1 2020 May 07, 2020	BUY	$7.54 - $17.05 $28,652 - $64,790	3,800 New	3,800 $43,000

27.1K

150K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $30.4M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.